Hyperpigmentation from Oxaliplatin, Calcium Leucovorin, and 5-Fluorouracil
Yes, 5-fluorouracil (5-FU) can cause hyperpigmentation, but this adverse effect is specifically attributed to 5-FU rather than oxaliplatin or calcium leucovorin (folinic acid).
Incidence Rate
The incidence of hyperpigmentation from 5-FU is not precisely quantified in major clinical guidelines or FDA labeling, but research evidence suggests it occurs with variable frequency depending on administration route and duration. The FDA label for oxaliplatin lists "pigmentation changes" as occurring in less than 5% but ≥2% of patients receiving oxaliplatin combinations 1, though this does not distinguish which component causes the effect.
Evidence Breakdown
Drug-Specific Attribution
5-Fluorouracil is the culprit agent:
- Multiple case reports and research studies document 5-FU-induced hyperpigmentation patterns including serpentine streaks, reticulate patterns, and genital area pigmentation 2, 3
- Recent mechanistic studies demonstrate 5-FU causes hyperpigmentation through the oxidative stress/NF-κB/ACTH/cAMP/tyrosinase pathway, with melanin accumulation in the basal epidermal layer 4
- Animal models show 5-FU increases tyrosinase expression, melanin synthesis, and blood vessel markers, leading to characteristic hyperpigmentation 5
- A 2026 meta-analysis reported antineoplastic agents have a pooled DIH incidence of 35.5% (95% CI: 0.291-0.444), though this encompasses multiple chemotherapy agents 6
Oxaliplatin and Calcium Leucovorin:
- Neither the ESMO guidelines 7, 8 nor NCCN guidelines 9 list hyperpigmentation as a recognized toxicity of oxaliplatin
- Oxaliplatin's characteristic toxicities are polyneuropathy, myelosuppression, and gastrointestinal effects 7
- Leucovorin (folinic acid) is not associated with pigmentation changes in any reviewed evidence
Clinical Context
When patients receive FOLFOX regimens (5-FU/leucovorin/oxaliplatin), any observed hyperpigmentation should be attributed to the 5-FU component. The ESMO guidelines emphasize that infused 5-FU/LV regimens are less toxic than bolus regimens 7, 8, which may influence pigmentation risk, though specific comparative data on hyperpigmentation incidence between infusion schedules is lacking.
Clinical Characteristics
Pattern Recognition:
- Hyperpigmentation from 5-FU appears with increasing frequency of administration 5
- Characteristic patterns include serpentine streaks appearing as early as 5 days post-infusion 3, reticulate hyperpigmentation 2, and melanin accumulation in the basal epidermal layer 5
- Sex differences exist: male mice develop genital area pigmentation while females show resistance, possibly due to estradiol-mediated suppression of ROS production 10
Mechanism:
- Involves ACTH elevation, reactive oxygen species, increased tyrosinase activity, and enhanced blood vessel formation 4, 5
- Melanin accumulation is the primary cause 5, 4
Management Implications
While the ESMO dermatological toxicity guidelines 11 extensively cover hand-foot syndrome (HFS) from 5-FU (incidence 6%-34% for 5-FU alone, 50%-60% for capecitabine), they do not provide specific management protocols for hyperpigmentation. This suggests hyperpigmentation is generally considered a cosmetic rather than dose-limiting toxicity, though it significantly impacts patient quality of life 5, 4.
Key Point: The FDA label notes "pigmentation changes" occur in the oxaliplatin combination arm 1, but this is a minor toxicity compared to the major concerns of neuropathy (92% incidence, 13% grade 3), myelosuppression (41-44% grade 3-4 neutropenia), and gastrointestinal toxicity that drive dose modifications in FOLFOX regimens 7, 1.